Biomedical Company Announces Advancements For Potential Adjustment Disorder Treatment

Psyence Biomedical Ltd. (Nasdaq: PBM), referred to as "Psyence Biomed" or "the Company", recently announced advancements in their ongoing efforts to explore nature-derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in a Palliative Care context. The latest developments include the successful export of their drug candidate, PEX010, to Australia and updates on their upcoming Phase IIb clinical trial. $Psyence Biomedical(PBM.US)$